Podcasts about Abstract

Los Dres. Fernando Aldaco y Homero Fuentes, oncólogos médicos mexicanos, comparten su análisis de los estudios más relevantes presentados durante el cuarto día de la Reunión Anual 2025 de la Sociedad Americana de Oncología Clínica, celebrada en Chicago, con base en la información disponible al momento de esta grabación.Los trabajos comentados son: Abstract #9510CheckMate 214 (Abstract #4505)CheckMate 816 (abstract #LBA8000)NeoADAURA (abstract #8001)IMforte (abstract #8006)DeLLphi-304 (abstract #LBA8008)PROSTest (abstract #5107)STAMPEDE (abstract #5001)BULLSEYE (abstract #5009)VIOLET (abstract #5010)Abstract #5013NeoCARHP (abstract #LBA500)Destiny-Breast09 (abstract #LBA1008)Fuentes:Abstracts presentados en el marco de la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO®) de 2025, Chicago, IL, EE.UU.

This week is devoted to older, classic abstract games. You probably know how to play these timeless games already, and have some of them relegated to the back corner of your shelves or your closet. The post Episode 398 – Room to Grow: Classic Abstract Games appeared first on The Family Gamers.

Dr. John Sweetenham shares highlights from Day 4 of the 2025 ASCO Annual Meeting, including new research on maintenance therapy in small cell lung cancer and a virtual reality psychosocial intervention for patients undergoing hematopoietic stem cell transplantation. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 4 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. Today's selection features reports of 3 randomized trials in very different clinical settings: maintenance therapy in extensive small cell lung cancer (SCLC), upfront surgery in advanced ovarian cancer, and a supportive care intervention for patients undergoing hematopoietic stem cell transplantation. The first of these studies, Abstract 8006, was presented by Dr. Luis Paz-Ares from the University Hospital [October 12] in Madrid, Spain, and reports the primary results of the IMforte trial. This was a phase 3 trial evaluating the combination of lurbinectedin and atezolizumab as first-line maintenance therapy in patients with extensive small cell lung cancer. Despite some improvements in the first-line treatment of extensive small cell lung cancer with the use of checkpoint inhibitors in combination with platinum-based chemotherapy, most of the patients experience early disease progression and long-term survival remains very limited. This provides a rationale for considering a maintenance intervention. Lurbinectedin is an alkylating agent and transcription inhibitor [that is] already approved in the United States for patients with relapsed/refractory metastatic SCLC following platinum-based chemotherapy. It has been shown to synergize with immune checkpoint inhibitors in pre-clinical studies and has also been evaluated in early-phase clinical trials. The IMforte trial is a global, randomized trial in which patients are initially treated with atezolizumab, and those patients who do not progress on induction therapy are then randomized to maintenance therapy with atezolizumab alone or atezolizumab with lurbinectedin. The primary endpoints of the study were progression-free and overall survival. Four hundred and eighty-three patients were randomized and at a median follow-up of 15 months, the median progression-free survival for patients who received the combination was 5.4 months and the median overall survival was 13.2 months. This compares with 2.1 and 10.6 months, respectively, in patients who received atezolizumab only. The lurbinectedin and atezolizumab combination was generally well-tolerated, with no new or unexpected safety signals. The benefit was consistent in magnitude across all the relevant patient subgroups. This is the first phase 3 study to show a progression-free and overall survivial improvement with first-line maintenance in extensive stage SCLC and the result is likely to be practice-changing, establishing a new standard of care in this tough-to-treat disease. Next up is LBA5500, presented by Dr. Sven Mahner from LMU University in Munich, Germany. This describes the results of the TRUST study, a randomized trial of upfront surgical therapy in advanced ovarian cancer. As background, total macroscopic tumor resection with maximal effort cytoreductive surgery is the cornerstone of treatment in patients with advanced ovarian cancer. The optimal timing of such surgery remains controversial, whether it's more beneficial as a primary cytoreductive surgery before chemotherapy or in the form of interval cytoreductive surgery after 3 cycles of neoadjuvant chemotherapy. Previous studies have addressed this issue, but results have been confounded by issues of patient and center selection. The TRUST study is a randomized, international, multicenter phase 3 trial that compares the outcomes of the timing of surgery in surgically fit patients with seemingly resectable FIGO stage IIIB/IVB ovarian, tubal, and peritoneal carcinoma. To ensure consistent and adequate surgical quality, participating centers in the trial were required to obtain accreditation and undergo an onsite quality assurance review. This included assessment of infrastructure, surgical proficiency, complete resection rates, and surgical volume. Seven hundred and ninety-seven patients with advanced ovarian cancer were randomized to undergo surgery prior to therapy with 6 cycles of carboplatin and paclitaxel along with bevacizumab and a PARP inhibitor, or to have the surgery between the third and fourth cycle of the same systemic therapy. Of the initial 797 patients, 688 comprised the intent-to-treat population, of whom 345 received primary cytoreductive surgery and 343 received neoadjuvant chemotherapy followed by interval cytoreductive surgery.  The results show that patients undergoing primary surgery had significantly improved progression-free survival compared with those who had interval cytoreductive surgery (median progression-free survival was 22.1 months versus 19.7 months). No difference in overall survival was observed between the 2 arms of the study.  This is the first study to show a benefit for primary cytoreductive surgery, although the progression-free survival improvement was not reflected in an overall survival difference. A subgroup analysis for patients who underwent complete cytoreduction suggests a progression-free survival and survival benefit, although it isn't clear to me that the study was powered for this endpoint. Nevertheless, these are very difficult studies to perform, and the investigators should be congratulated for this robustly conducted clinical trial. Today's final abstract is 1504, presented by Dr. Hermioni Amonoo from Harvard Medical School. The trial evaluated BMT-VR, a virtual reality psychosocial intervention for patients undergoing bone marrow transplantation. This randomized trial included adult patients undergoing autologous and allogeneic transplantation. The BMT-VR platform included, among others, modules addressing psychoeducation, coping, acceptance, and gratitude. BMT-VR patients were provided with VR headsets and completed all modules during their hospitalization. Patient-reported outcomes were then assessed at 2, 4, 12, and 24 weeks post-BMT. Use of the VR tool was tracked during hospitalization. Control patients received usual care during their hospital stay and were then assessed at the same intervals post-BMT.  Eighty evaluable patients were randomized, 39 to BMT-VR and 41 to usual care. Completion rates for the BMT-VR modules were high [at] around 70-75%.  Patients who received the BMT-VR intervention experienced significantly improved anxiety, quality of life, and coping at 4 weeks post-BMT. In the longer term, sustained benefits were seen at 24 weeks for some endpoints including quality of life, with some benefits, including for depression and PTSD symptoms, improving longitudinally over the study period. These data are preliminary and will need to be confirmed in larger multicenter studies, but this trial demonstrates the feasibility of using virtual interventions in our patients and also provides intriguing preliminary data that they may be effective. Thanks for listening to today's report and I hope you will join me again tomorrow to hear more top takeaways from the final day of ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:     Dr. John Sweetenham       Follow ASCO on social media:      @ASCO on Twitter     @ASCO on Bluesky     ASCO on Facebook     ASCO on LinkedIn       Disclosures:    Dr. John Sweetenham:     No relationships to disclose 

The letter of Romans strengthened the ancient church, brought reformation to the dark ages, has brought hope for 2000 years, and can change your life!This week Pastor Joel continues Part 2 of his message series in the book of the Bible called Romans, “Bold Faith That Wins”. This week, Joel continues to look at one of the most controversial texts in the Bible, Romans chapter 9. In verses 14-29 we see a two-fold reminder: 1) Our perception does not determine reality, particularly when it comes to justice. 2) And that the universe does not revolve around me. Remember who you are, who God is, who God makes us to be, and what could have been. This is a special four part series that will span the year of 2025.LINKS + RESOURCES FROM THIS EPISODE:• Recommended reading for this series• The Abstract of Principles, 1859; Westminster Confession, 1646; Baptist Faith and Message, 1963, 2000; Hymn “Pass Me Not, O Gentle Savior”; C.S. Lewis; Christopher Watkin; Tim Keller; A.A. Hodge• Download the free study guide by visiting and clicking on the button "Download Study Guide"⁠• Find a complete transcript here• Scripture References: Romans 9, verses 14-29; Romans chapters 1-3; Exodus 7, verses 3-4• Find out more about Covenant Church at ⁠covenantexperience.com

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.  Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode.  Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence.  Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor.  Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group.   For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group.  The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases.  The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them.  The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma.  Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks.  Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination.  These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report.  The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia.   Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis.  Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%.  The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed.  This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context.  Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker:   Dr. John Sweetenham   Follow ASCO on social media:    @ASCO on Twitter   @ASCO on Bluesky   ASCO on Facebook   ASCO on LinkedIn    Disclosures:   Dr. John Sweetenham:   No relationships to disclose  

Abstract anatomy art on the walls or bumping Pitbull every Friday are just a couple ways ATs turn the clinic into a home. ATs share their stories of the good, the bad, and the unique things about their athletic training clinic/facility/room.Featuring stories from Jackson B, Jessica J, Marc W, Marissa S, Meghan M, Courtney P, Miguel M, Alex S, Zoe H, a Kool one from Kevin, Alberto H, Mick H, & many more! --AT CORNER FACEBOOK GROUP: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/groups/atcornerpodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram, Website, YouTube, and other links: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠atcornerds.wixsite.com/home/links⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠EMAIL US: atcornerds@gmail.comSAVE on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbridge⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: Use code ATCORNER to get $101 off your subscriptionWant to host a podcast like ours? Use our link to sign up for Zencastr, the service we use to record our interviews: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://zencastr.com/?via=atcorner⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Music: Jahzzar (betterwithmusic.com) CC BY-SA---Sandy & Randy

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

Let's practice some common Spanish abstract nouns, including nombre, tipo, historia, and poco. Practice all of today's Spanish for free at LCSPodcast.com/74  

Send us a textIn this episode, we delve into the practice of Sydney-based artist Kyle Murrell, whose abstract works explore the tension between structure and meaning. A 2013 Honours graduate of the National Art School, Murrell has garnered accolades including the John Olsen Prize for Figure Drawing and the Elioth Gruner Prize for Landscape Painting . His process is rooted in drawing, serving as both exploration and regeneration, leading to paintings that deconstruct and obscure subjects through layered mark-making .Murrell's commitment to abstraction earned him the 2019 Defiance Award, granting a residency with the Nock Art Foundation in New Zealand . Represented by Defiance Gallery, his recent exhibitions include New Paintings and the upcoming Always At Every Moment (31 May – 21 June 2025) . Join us as we discuss his evolving practice, the role of repetition, and how drawing sustains his creative journey.Thanks Kyle

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Executive Summary:This document summarizes key instructions and guidelines provided for the completion of the first draft of the thesis paper and preparation for the mock presentations. The sources emphasize adherence to formatting requirements (APA 7th edition), content guidelines for specific sections (Abstract, Introduction, Literature Review, Method, Results/Discussion, Conclusion, Appendices, References), and preparation strategies for the mock presentations, including content, delivery, and technical aspects. Key themes include attention to detail in formatting, summarizing the paper effectively, and practicing delivery and anticipating questions for the presentation.Key Themes and Ideas:* Hard Copy Draft Review: Students are required to submit a hard copy of their first completed draft. A quick self-review in groups is encouraged, focusing on specific formatting elements.* Headings: Check that all headings (except in the method section) have 6 to 12 words. Main words should be capitalized. No punctuation should be at the end of any heading. Method section headings (Participants, Instruments, Procedure, Data Analysis) can be shorter.* Page Breaks: Specific pages should be on their own page: Title page, Authorization page, Abstract, Table of Contents, Figures/Tables (if applicable), and each Appendix. The body of the paper (Literature Review through the Conclusion paragraph) should have no page breaks.* Spacing: The entire paper should be double-spaced, with no extra space between paragraphs, headings, and text. References are an exception, with single spacing within the reference and double spacing between references.* Indentation: Each paragraph, except for the Abstract, should have a half-inch indentation.* Paragraph Count: The Abstract, Participants, Instruments, Procedure, and Data Analysis sections should each consist of only one paragraph. The final paragraph of the paper is considered the Conclusion paragraph and does not require a separate "Conclusion" heading.* Appendix Formatting: Each appendix should start on a new page with a Level 1 heading (e.g., "Appendix A") at the very top line, followed by a Level 2 heading for the appendix title.* Title Recommendations: The instructor suggests using ChatGPT to generate title ideas now that the paper is mostly complete.* If the title is longer than one line, force a return to distribute words more or less equally across two lines.* Single-space the title.* Improving Writing (Verb Usage): Students are encouraged to review their paper for overuse of the verbs "to have," "to be," and "to make" (as lexical verbs). While not forbidden, excessive use may indicate areas for improvement by substituting more dynamic verbs, often converting nouns into verbs. The instructor provides an example of how to rewrite sentences to be more concise and dynamic.* Mock Presentation Structure and Timing: The mock presentation is 20 minutes long with a 10-minute Q&A. The entire class scheduled for a specific day is expected to observe all presentations on that day.* Suggested Slide Order: Title slide, Problem and Purpose, Literature Review (multiple slides), Method, Results and Discussion (multiple slides), Conclusions, Thank You.* Approximate Timing: Problem and Purpose (30 seconds to 1 minute), Literature Review (approximately 8 minutes), Method (approximately 2 minutes), Results and Discussion (approximately 9-10 minutes).* Presentation Content: Present only the essential information that directly relates to the research questions and analyzed data. Do not attempt to present everything from the written paper due to time constraints.* Mock Presentation Delivery and Technical Aspects:* Preparation: Practice the presentation, ideally recording oneself and timing each section. Consider practicing in front of someone.* Slides: Slides are meant to support the speaker, not to be read directly. They should function as "big note cards" with key points or ideas. Each slide should focus on one main point and include a heading. Avoid paragraphs and excessive text on slides.* Visuals: Make slides visually appealing but not distracting. Use visuals like graphs, charts, tables, and images from the paper, simplifying or modifying them for the presentation. Use no more than three different font styles and sizes, and choose easy-to-read fonts. Avoid animations and complex color schemes that might reduce contrast.* Technology: Coordinate with classmates to use one computer for presentations on a given day. Test equipment beforehand, turn off automatic updates, and ensure the computer is fully charged and doesn't go to sleep. Have a backup of the presentation file (e.g., on a USB drive in addition to the computer).* Delivery: Focus on the message, not personal nervousness. Maintain eye contact with the audience, specifically the examiners during the final defense, distributing attention among them. Bring a water bottle.* Anticipate Questions: Prepare for potential questions, including definitions of key terms used in the study.* Final Oral Defense Considerations:* Similar guidelines to the mock presentation, but attendance is by invitation only (family, friends, classmates).* Coordinate bringing refreshments for the examiners.* Arrive at least 30 minutes early with guests.* Maintain eye contact, especially with examiners.* No microphone is expected to be needed; speak loudly and project.* Present from the stage or on the floor in front of the stage, based on comfort.* Paper Submission: Submit three hard copies of the first completed draft. Confirm that the version in Microsoft Teams is the same as the hard copy. The final paper (Word document and three hard copies) is due officially one week before the scheduled presentation.Quotes:* "Make sure that the headings all of the headings have 6 to 12 words except for the headings in the method section."* "Check each heading to make sure that the main words are capitalized."* "Finally, check at the end of each heading. No punctuation, no period, no colon, no. Nothing."* "The body of the paper, there are no page brakes."* "Make sure each appendix has a page break and appears at the very top line."* "Make sure that each paragraph with the exception of the abstract has a half of an inch indentation."* "Look at the abstracts. Each section of the method and your conclusion to make sure you only have one paragraph."* "Today, I'm going to receive your uh hard copies of your first completed draft. This is an important milestone, right?"* "Today I want to spend just a few minutes very quickly all of us taking a look at your document, making a few notes very very quick."* "I would recommend trying and experimenting with chatt to give you some ideas of titles now that your paper has been completed."* "If your title extends longer than one line... force a return... single space the title."* "I want you to see how many times you're using three birds. to have, to be, to make."* "The problem in general is when we're using a bunch of times these verbs voice passive and there is there are. The problem is we have a lot of nouns that could be converted to a verb."* "We need to be prepared on Monday, well, whenever you're presenting, for a 20 minute presentation with a 10 minute question and answer."* "Remember your presentation is there to support what you are saying, not vice versa."* "Think of the the PowerPoint presentation the slides as big cards note cards."* "We don't want any distractions, right? It's a distraction when you're speaking and somebody's coming in and out."* "Maintain eye contact... try to connect to those examiners because they're the ones that are going to give you the grades."Source 2: Excerpts from "TS Recap 15.mp4"This source provides a recap of Week 15 for Thesis Seminar, focusing on the requirements for the first completed draft of the thesis paper due the same week.Key Themes and Ideas:* First Completed Draft Requirements: The first completed draft is due as a hard copy. Students should refer to the course guidelines for detailed requirements, including approximate word counts.* Introduction Paragraph: Should start with a hook, provide context for the problem, and end with the thesis statement.* Transitional Paragraph: Should restate the thesis statement, summarize the problem, introduce the research questions, and conclude with a closing statement.* Conclusion Paragraph (End of Results and Discussion): Approximately 250 words. Should begin by restating and rewording the thesis statement, discuss study limitations and significance, suggest future research, and end with a closing statement.* Abstract: Should be on its own page, follow the provided template, and be one paragraph of approximately 250 words. It should summarize the entire paper: problem, method (participants, data collection, analysis), findings, and conclusions/implications. It serves as a snapshot for readers to decide if they want to read the full paper.* Formatting (Reinforced):Title: 6 to 12 words.* Spacing: Double-spaced throughout the paper (except references).* Alignment: Left-justified.* Indentation: 0.5-inch indentation for all paragraphs except the Abstract.* References: Adhere to APA 7th edition. Use a hanging indent (French indentation). Single-space within each reference and double-space between references.* Appendices: Each appendix on a new page with a Level 1 heading ("Appendix A," etc.) and a Level 2 heading for the title. Use the specified font styles (Level 1 APA, Level 2 APA, etc.) for headings.* Table of Contents: Should be updatable based on correctly formatted headings.* Approximate Word Counts: Provides word count guidelines for major sections: Literature Review (approx. 2250 words), Results and Discussion (approx. 2250 words), Method (approx. 500 words, divided among Participants, Instruments and Procedure, Data Analysis).Quotes:* "This week, we need to finish our first draft. And today, I want to talk about what should be included in your completed first draft. Uh a hard copy that you're to turn in by noon this Thursday, May 22nd, 2025."* "Make sure that you've uh reviewed the course guidelines that are available in Microsoft Teams... it includes a section with approximate word counts."* "Your paper should include an introductory or an introduction paragraph... make sure that the uh the introduction paragraph begins with a hook. It offers the context of the problem and it concludes by stating your thesis statement."* "The conclusion paragraph to end your results and discussion section should be approximately 250 words and begin again with your thesis statement restated and rewarded."* "After restating your thesis statement, you can talk about um any limitations that you find... include the significance of your study and also future research."* "The abstract should be on its own page... Should be one paragraph, approximately 250 words, and should state basically summarize uh your whole paper."* "Think of the abstract as a kind of a snapshot of your whole paper."* "Make sure you have a title of your paper, 6 to 12 words."* "Your whole paper should be double spaced, left justified."* "All paragraphs should have a uh 0.5 in indentation with the exception of the abstract."* "Double check your list of references making sure that they adhere to APA 7th edition."* "Make sure you using a French indentation or a uh a hanging indent."* "Each appendix should have a level one heading that states which appendix it is... And then as a level two, I would include the title of the of the appendix."Conclusion:Both sources provide essential guidance for completing the thesis paper draft and preparing for the mock presentations. The first source delves deeply into specific formatting checks and detailed presentation strategies, while the second source provides a concise overview of the key components and formatting requirements for the written draft. Students are strongly encouraged to meticulously review their drafts against the provided guidelines, practice their presentations thoroughly, and anticipate questions to ensure a successful mock presentation and final defense. Attention to detail in both the written document and the presentation delivery is paramount.Recap for Week 15Configuring tables and figures This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit benjaminlstewart.substack.com

Conflict Management and Resolution with Destiny F. Chau MD, FAAP, MSLOD, ACC

While other L2s fight technical battles, Abstract is creating something entirely different: a "digital Disneyland" that's all about fun.In today's episode, we chat with Luca Netz and Michael Lee "Cash Bowie," to explore how this playful approach is driving real traction:- Portal is bringing 25,000+ users to quality apps in a snap- Builders with solid monetization are generating $500K+ monthly- The Pudgy Penguins playbook is catching the eye of top global brandsFrom distribution to consumer crypto, and everything in between, you'll get the full picture of the Abstract playbook.Let's jump in.---Newton is the trust layer for autonomous finance. Smart. Secure. Verifiable. Built for a future where AI agents replace apps and interfaces. Learn more here: https://www.magicnewton.com/----

Hannah Thomas paints dreamlike, abstract landscapes full of weird biomorphic shapes, hybrid creatures and visceral body parts full of symbols and metaphor. In this episode, she talks about her previous career as a photographer shooting rock musicians, why she gave up photography for painting, her instinctive process often inspired by music, her interest in Absurdism,... Continue Reading →

Our Abstract Series returns with an absolute classic. This one is as abstract as it gets! It's “Abstract Color Blasts!” on this week's TrekRanks! What's an “Abstract Color Blast!” you ask? Well, listen in and figure it out with our panel of host Jim Moorhouse and expert color analysts Ross Webster and Anika Dane, who come at this topic from every angle. One thing we learn for sure is that an “Abstract Color Blast!” can literally come from anywhere and be anything in Star Trek! This is a colorful conversation you will not want to miss! Episode Rundown: Diagnostic Cycle: Where we briefly get into the details of defining the show's specific topic and run through our “Abstract Series” roll call of 10 previous topics! Prime Directive: Each guest on this week's panel reveals exactly how they narrowed down their list and made their final choices. The Order of Things: All the picks are revealed with the TrekRanks' original “Five words and a hashtag” summary, along with one episode that helps frame their choice. Secondary Systems: For a few extra picks that just missed our final list. Regeneration Cycle: The panel recaps their picks and we dissect some of the interesting statistical anomalies that arose from the discussion (including our ROY G BIV breakdown). Temporal Inversion: We flashback to a previous episode of TrekRanks and relay a voicemail from one of our listeners. If you have your own picks you would like to relay to us, please hail us at 757-828-RANK (7265) and record your own personal TrekRanks log to let us know your Abstract Color Blasts! (Or you can record it yourself and just DM us @TrekRanks.com on Bluesky.) Your comments could be used as part of a Temporal Causality Loop on an upcoming episode (and might get you a chance to be a guest on a future episode, too). And don't forget to check out TrekRanks.com for our entire back catalog of episodes and a detailed rundown on every episode of Star Trek ever.      

Click on Image Above to View Sermon Video

  The Ruckus Report Quick take: International school leader Jennifer Bertram reveals how trusting your intuition can lead to unexpected leadership opportunities, and how joining a supportive community of fellow leaders transforms professional growth. Meet Your Fellow Ruckus Maker Originally from Canada, Jennifer's teaching journey began in Montevideo, Uruguay, followed by many years at Escola Americana de Campinas, Brazil. She transitioned to administrative roles including Secondary Dean of Students and Assistant Principal. Jennifer then served as Middle School Principal at the American International School of Dhaka for five years before moving to American International School Chennai with her family. Breaking Down the Old Rules

May is Mental Health Awareness Month, so we've pulled together some of the most vital stories from some of the star legal and business experts we've featured on The Abstract about managing stress, achieving a healthy work/life balance, dealing with tragedies at home, leaving toxic working environments and more. Keep listening and feel inspired to make a positive change in your life and career.Read detailed summary: https://www.spotdraft.com/podcast/episode-98TopicsIntroduction: 0:00 Ryan Nier, General Counsel at Nova Credit on imposter syndrome and feeling like an outsider in the legal community: 0:43 Joe Sullivan, ex-Chief Security Officer at Uber, Facebook, and Cloudflare on managing the stress of a federal indictment: 6:49 Lawtrades Co-Founders Raad Ahmed and Ashish Walia on how to support your business partner during difficult times: 11:36 Dan Haley, General Counsel and Corporate Secretary at Guild, on balancing work and life after a cancer diagnosis: 14:07 Zoe McMahon, Head of Legal Ops at HP, on mindfulness and bringing parts of your private self into the workplace: 16:47 Laura Frederick, CEO of How to Contract on the importance of seeing a therapist: 18:59Connect with us:Tyler Finn - https://www.linkedin.com/in/tylerhfinnSpotDraft - https://www.linkedin.com/company/spotdraftSpotDraft is a leading contract lifecycle management platform that solves your end-to-end contract management issues. Visit https://www.spotdraft.com to learn more.

Slam this button to send us a message! All wrestling opinions welcome!On this edition of the Sit Down Marks Podcast, DB Sits Down with Independent Professional Wrestler, The Problem Solver, Xac Abstract. Xac talks his grind in wrestling so far, tours in Mexico & Japan & his wrestling roots & much more! Available on YouTube & Facebook. Audio Available on Spotify, Apple Podcasts, Audible, iHeart Radio, Sportzwire Radio & More! (Episode 159) Buy the show a coffee! Sit Down Marks! Merch SportzWire Radio Hall of Fame Podcast!! Want to Advertise or Market Your Product or Service to our Fanbase? Email dbonthemic@yahoo.com or Follow @SitDownMarks on Social Media and Message us there! #SpreadTheGoodWordofWrestling

Click image above to watch video.

01.James Hype - Don't Wake Me Up (Vibe Chemistry Remix) 02.Foor & Effie - Fire 03.Tantrum Desire, Ayah Marar - Something Real 04.Phaze - Darkest Hours 05.Flowidus & Cecelia - Fever Thoughts 06.Grafix & Nu-La - Vital Signs 07.Evergreen - Dundie 08.Plago - Pozovi Menia 09.Maduk - See It Through 10.Jurassic, DJ 007 - Remembering 11.sless, Loboski & Veronica Bravo - Heart Less 12.Martin Garrix, Mesto - Limitless (Arcando Remix) 13.Sicknote - Shock 14.Madface - Mugeni 15.T-Trider - To The Limit 16.Feed the Fire - Turn Up 17.TURNO/Riko Dan - Outta Order 18.Ekko & Sidetrack - Le Push 19.Zardonic & Reebz - Bitter (AVERTED Remix) 20.Karacha - I Chose the Life 21.Toronto Is Broken, Reebz & Sebotage - SOMEWHEREIBELONG 22.Gancher & Ruin - PSYOP 23.Emzee & Yimura - SlaughterHouse 24.KNARS - Where Is Your Head At 25.Imanu/Flux Pavillion/Tasha Baxter - Kintsugi 26.Dj Diesel & Ivory feat. Shaquille O'Neal - Run It 27.Donny - Life (DJ Hidden Remix) 28.Audio & Donny - Horribly Ribbed (Zombie Cats Remix) 29.Mayel - Diversion 30.NERV3 - Construct 31.Joe Ford, Task Horizon, The Velvet Effect - Where Is The Moon? 32.2Whales - Hrupen 33.2Whales - Dark Sun 34.Dizlunr - Over the Horizon 35.Benny V, K-Warren, Haley McCabe - You Are 36.Capital Dogz & UZI - Binary Star 37.XHL & Monyu - Fission 38.Andy Pain - Full Moon 39.Moonaddict - Shuffle the Deck 40.Holographic - Pharaoh 41.DannyLO - Whiskey Sour 42.Klinical, Koherent - Feelings 43.Kampion - 4U 44.Geostatic, Dub Ten - Feral Funk 45.Abstract, Freddy B - Diggin 46.Instant - Feel The Bass 47.Big Boss - This track sick bruv 48.Conrad Subs - Fatboi 49.Think Tonk, Alibi - Run to the Night 50.Rua Tui & Kathika - Lighters Up 51.Friction & Basslayerz - Shoot 52.Røki - Rico 53.Dunk - Yellow Jacket 54.Teddy Killerz/Sweetie Irie - Tonight 55.sola/Conrad Subs - Smash Up 56.Heathen - Serious Ting 57.Ponz - I Can't Change You 58.Forum - Beskar 59.Offish & Red Army - Sulfur 60.Jonny L - Long Long Time 61.Duburban - Breaking Point 62.Hyper-On Experience - Half Stepper (Madcap Remix) 63.Dom & Roland - A Life Of Chance 64.Kometa & Sonic Art - Break In 65.Offish & Evasion - Ash Cloud 66.Biorhythm - Bathed In Light 67.Quentin Hiatus - Gengar's Castle 68.Subp Yao - That Bounce 69.Fearful - Dark City 70.Bop x Chime - Dormant 71.Degs - If We Left This Earth 72.Technimatic & Ruth Royall - Time On Our Side 73.In:Most - 4EVER 74.London Elektricity - All On Top (feat. Conrad Subs & Genesis Elijah) 75.Northern Zone - People Changed 76.Askel & Elere - The Light Feels Low 77.Eastcolors - Waves (Maykors Remix) 78.ID-S - All Is Full Of Love 79.SOLR, Kr33per - YGM 80.Noiger - Tell Me Where You Go 81.Unknown Artist - Amalfi Coast Drive 82.Driverufo - Distant Shores 83.antoanesko - Mellow Tides

01.James Hype - Don't Wake Me Up (Vibe Chemistry Remix) 02.Foor & Effie - Fire 03.Tantrum Desire, Ayah Marar - Something Real 04.Phaze - Darkest Hours 05.Flowidus & Cecelia - Fever Thoughts 06.Grafix & Nu-La - Vital Signs 07.Evergreen - Dundie 08.Plago - Pozovi Menia 09.Maduk - See It Through 10.Jurassic, DJ 007 - Remembering 11.sless, Loboski & Veronica Bravo - Heart Less 12.Martin Garrix, Mesto - Limitless (Arcando Remix) 13.Sicknote - Shock 14.Madface - Mugeni 15.T-Trider - To The Limit 16.Feed the Fire - Turn Up 17.TURNO/Riko Dan - Outta Order 18.Ekko & Sidetrack - Le Push 19.Zardonic & Reebz - Bitter (AVERTED Remix) 20.Karacha - I Chose the Life 21.Toronto Is Broken, Reebz & Sebotage - SOMEWHEREIBELONG 22.Gancher & Ruin - PSYOP 23.Emzee & Yimura - SlaughterHouse 24.KNARS - Where Is Your Head At 25.Imanu/Flux Pavillion/Tasha Baxter - Kintsugi 26.Dj Diesel & Ivory feat. Shaquille O'Neal - Run It 27.Donny - Life (DJ Hidden Remix) 28.Audio & Donny - Horribly Ribbed (Zombie Cats Remix) 29.Mayel - Diversion 30.NERV3 - Construct 31.Joe Ford, Task Horizon, The Velvet Effect - Where Is The Moon? 32.2Whales - Hrupen 33.2Whales - Dark Sun 34.Dizlunr - Over the Horizon 35.Benny V, K-Warren, Haley McCabe - You Are 36.Capital Dogz & UZI - Binary Star 37.XHL & Monyu - Fission 38.Andy Pain - Full Moon 39.Moonaddict - Shuffle the Deck 40.Holographic - Pharaoh 41.DannyLO - Whiskey Sour 42.Klinical, Koherent - Feelings 43.Kampion - 4U 44.Geostatic, Dub Ten - Feral Funk 45.Abstract, Freddy B - Diggin 46.Instant - Feel The Bass 47.Big Boss - This track sick bruv 48.Conrad Subs - Fatboi 49.Think Tonk, Alibi - Run to the Night 50.Rua Tui & Kathika - Lighters Up 51.Friction & Basslayerz - Shoot 52.Røki - Rico 53.Dunk - Yellow Jacket 54.Teddy Killerz/Sweetie Irie - Tonight 55.sola/Conrad Subs - Smash Up 56.Heathen - Serious Ting 57.Ponz - I Can't Change You 58.Forum - Beskar 59.Offish & Red Army - Sulfur 60.Jonny L - Long Long Time 61.Duburban - Breaking Point 62.Hyper-On Experience - Half Stepper (Madcap Remix) 63.Dom & Roland - A Life Of Chance 64.Kometa & Sonic Art - Break In 65.Offish & Evasion - Ash Cloud 66.Biorhythm - Bathed In Light 67.Quentin Hiatus - Gengar's Castle 68.Subp Yao - That Bounce 69.Fearful - Dark City 70.Bop x Chime - Dormant 71.Degs - If We Left This Earth 72.Technimatic & Ruth Royall - Time On Our Side 73.In:Most - 4EVER 74.London Elektricity - All On Top (feat. Conrad Subs & Genesis Elijah) 75.Northern Zone - People Changed 76.Askel & Elere - The Light Feels Low 77.Eastcolors - Waves (Maykors Remix) 78.ID-S - All Is Full Of Love 79.SOLR, Kr33per - YGM 80.Noiger - Tell Me Where You Go 81.Unknown Artist - Amalfi Coast Drive 82.Driverufo - Distant Shores 83.antoanesko - Mellow Tides

Пиратская Станция предлагает ощутить поток энергии и красоты с помощью свежести и изысканности drumandbass релизов, которые мы регулярно запускаем на радио Рекорд! Эфир продолжает весенний движ и призывает присоединиться к нашему качу... GVOZD vibez: 1.James Hype - Don't Wake Me Up (Vibe Chemistry Remix) 2.Foor & Effie - Fire 3.Tantrum Desire, Ayah Marar - Something Real 4.Phaze - Darkest Hours 5.Flowidus & Cecelia - Fever Thoughts 6.Grafix & Nu-La - Vital Signs 7.Evergreen - Dundie 8.Plago - Pozovi Menia 9.Maduk - See It Through 10.Jurassic, DJ 007 - Remembering 11.sless, Loboski & Veronica Bravo - Heart Less 12.Martin Garrix, Mesto - Limitless (Arcando Remix) 13.Sicknote - Shock 14.Madface - Mugeni 15.T-Trider - To The Limit 16.Feed the Fire - Turn Up 17.TURNO/Riko Dan - Outta Order 18.Ekko & Sidetrack - Le Push 19.Zardonic & Reebz - Bitter (AVERTED Remix) 20.Karacha - I Chose the Life 21.Toronto Is Broken, Reebz & Sebotage - SOMEWHEREIBELONG 22.Gancher & Ruin- PSYOP 23.Emzee & Yimura - SlaughterHouse 24.KNARS - Where Is Your Head At 25.Imanu/Flux Pavillion/Tasha Baxter - Kintsugi 26.Dj Diesel & Ivory feat. Shaquille O'Neal - Run It 27.Donny - Life (DJ Hidden Remix) 28.Audio & Donny - Horribly Ribbed (Zombie Cats Remix) 29.Mayel - Diversion 30.NERV3 - Construct 31.Joe Ford, Task Horizon, The Velvet Effect - Where Is The Moon? 32.2Whales - Hrupen 33.2Whales - Dark Sun 34.Dizlunr - Over the Horizon 35.Benny V, K-Warren, Haley McCabe - You Are 36.Capital Dogz & UZI - Binary Star 37.XHL & Monyu - Fission 38.Andy Pain - Full Moon 39.Moonaddict - Shuffle the Deck 40.Holographic - Pharaoh 41.DannyLO - Whiskey Sour 42.Klinical, Koherent - Feelings 43.Kampion - 4U 44.Geostatic, Dub Ten - Feral Funk 45.Abstract, Freddy B - Diggin 46.Instant - Feel The Bass 47.Big Boss - This track sick bruv 48.Conrad Subs - Fatboi 49.Think Tonk, Alibi- Run to the Night 50.Rua Tui & Kathika - Lighters Up 51.Friction & Basslayerz - Shoot 52.Røki - Rico 53.Dunk - Yellow Jacket 54.Teddy Killerz/Sweetie Irie - Tonight 55.sola/Conrad Subs - Smash Up 56.Heathen - Serious Ting 57.Ponz - I Can't Change You 58.Forum - Beskar 59.Offish & Red Army - Sulfur 60.Jonny L - Long Long Time 61.Duburban - Breaking Point 62.Hyper-On Experience - Half Stepper (Madcap Remix) 63.Dom & Roland - A Life Of Chance 64.Kometa & Sonic Art - Break In 65.Offish & Evasion - Ash Cloud 66.Biorhythm - Bathed In Light 67.Quentin Hiatus - Gengar's Castle 68.Subp Yao - That Bounce 69.Fearful - Dark City 70.Bop x Chime - Dormant 71.Degs - If We Left This Earth 72.Technimatic & Ruth Royall - Time On Our Side 73.In:Most - 4EVER 74.London Elektricity - All On Top (feat. Conrad Subs & Genesis Elijah) 75.Northern Zone - People Changed 76.Askel & Elere - The Light Feels Low 77.Eastcolors - Waves (Maykors Remix) 78.ID-S - All Is Full Of Love 79.SOLR, Kr33per - YGM 80.Noiger - Tell Me Where You Go 81.Unknown Artist - Amalfi Coast Drive 82.Driverufo - Distant Shores 83.antoanesko - Mellow Tides

Yellow Swans "Untitled"John Davis "Untitled"No UFO's "Anthropomorphic Clouds of Smoke"Zelienople "More Mess"Gregg Kowalsky "VI-VII"Ilyas Ahmed "As Another"Common Eider, King Eider "Earth Liver"Jon Porras "Grey Dunes"Grouper "Cover The Windows And The Walls"

Maverick and artist Dustin Caballero explore the competitive nature of the art world, the evolution of artistic style, and the importance of creating art for oneself rather than for others. Dustin shares insights into his creative process, the challenges of navigating the art business, and the significance of community support. The discussion also touches on the impact of external factors on the art industry and the intersection of art and personal style, including sneaker culture.Rubiel Art:https://www.rubielart.comhttps://www.instagram.com/rubielartMaverick Podcast:

春天和夏天之交，发现了Miku Gaze！主播：拉帝｜奇妙导演，小红薯：拉帝Timeline：02:50 《Showbiz！》- Mike06:08 《Albion Files》- Terrace Martin08:53 《ALONE》- OMSB14:03 《渋響》- 渋さ知らズ18:42 《Another Planet》- nerdneko21:52 《ナガレモノノ儀》- Nakanoise

Click the image above to watch the sermon video.

Abstract neurographic artist Ayiana Viviana shares how reconnecting with Puerto Rico, battling inner struggles, and choosing self-trust transformed her art—and her life—with new courage, clarity, and creative depth.How a return to Puerto Rico—and a visit to an Indigenous site—recharged her spirit and creativityNeurographic art as emotional release: painting through pain, grief, and unseen feelingsListening to the second voice: surviving a mental health crisis and finding a new path through paintingDreams, risk, and reward: the story behind a $5,000 mural project and stepping into full creative worthPhilly's evolving arts scene: fighting for funding access and empowering artists at the grassroots levelOn building a slower, fuller life: why downtime, reading, and reflection now fuel her best workWant to hear more about Ayiana's early creative journey? Listen to her first conversation from 2023 here: Art and Emotion | Ayiana Viviana's Porter's Creative Exploration.This episode was recorded during a season celebrating growth, resilience, and the artists who show us what it means to turn life into art. Host: Rob LeeMusic: Original music by Daniel Alexis Music with additional music from Chipzard and TeTresSeis. Production:Produced by Rob Lee & Daniel AlexisEdited by Daniel AlexisShow Notes courtesy of Rob Lee and TransistorPhotos:Rob Lee photos by Vicente Martin for The Truth In This Art and Contrarian Aquarian Media.Guest photos courtesy of the guest, unless otherwise noted.Support the podcast The Truth In This Art Podcast Fractured Atlas (Fundraising): https://www.fracturedatlas.orgThe Truth In This Art Podcast Bluesky: https://bsky.app/profile/thetruthinthisart.bsky.socialThe Truth In This Art Podcast Instagram: https://www.instagram.com/truthinthisart/?hl=enThe Truth In This Art Podcast Website: https://www.thetruthinthisart.com/The Truth In This Art Podcast Shop: Merch from Redbubble ★ Support this podcast ★

On this episode of Banking on KC, artist Sheron Smith joins host Kelly Scanlon to share how KC's jazz influences, architectural beauty and her own emotional expression come together in her jazz, cityscape and abstract artwork. Tune in to discover:How Sheron brings historic jazz clubs and Kansas City landmarks to life with bold, expressive color.What draws her to abstract art and the versatile techniques she uses to create it.Why Kansas City's artistic community inspires and nurtures her work.How she balances creativity and entrepreneurship to build a sustainable art career.Country Club Bank – Member FDIC

This is an exciting re-release, a compilation of my conversations with abstract painters. All of these artists are smart and talented with a keen sense of how we relate to the world around us. Be sure to check out the full Eager To Know episodes for all 5 of these artists:   A New World Artist Darren Jones Jeff Cote The Choice Parade Sheila Arora Painter William Conger   Links to all 7 episodes can also be found at: eager2know.com

Pere Ubu "Chinese Radiation" Pere Ubu "Goodbye"Mirrors "She Smiled Wild"The Girls "Elephant Man"Pressler-Morgan One Plus One "You're Gonna Watch Me"15:60:75 "Behind Your Eyes"Devo "Smart Patrol/Mr. DNA"Dead Boys "Not Anymore"Dead Boys "Ain't Nothin to Do"Pagans "Dead End America"Pagans "Little Black Egg"Electric Eels "Spin Age Blasters"Electric Eels "Bunnies"Screaming Urge "Do You Think I'm Strange?"Bone Thugs-N-Harmony "For Tha Love of $ (Tha Yella Mix 9 Minutes Uv Funk)"

Learn more at TheCityLife.org

So often we skip the greeting but what is Paul trying to tell us? Why is the greeting important?Scripture:Romans 1:1-7Resources:FaceBook- FCC Young AdultsInstagram- @fccyaEmail- fccyadmin@fccsantamaria.orgWebsite- fccsantamaria.org

In this week's episode we'll cover Foundations of Metropolis, our Game of the Week, discuss Variable Setups in The School of Gaming,  and wrap it up by revealing our High-Five Abstract Games!  We also Spotlight A Gentle Rain from Incredible Dream!00:00:00 - Introductions & Awesomeness00:09:30 - Spotlight: A Gentle Rain00:19:03 - Game of the Week: Foundations of Metropolis00:49:10 - School of Gaming: Variable Setup in Board Games01:02:49 - High-Five: Abstract Games

Restaking is the hot new DeFi gamble — but do you really know how it works? In this quick breakdown, we cover how EigenLayer lets you double-stake ETH, rent out Ethereum's trust, and take on massive hidden risk. It's brilliant. It's dangerous. It's very, very crypto.

This week we're covering anti-intellectualism: what is it, who's involved, is there room to grow? Hope you like *light* mental lifting (don't worry I'll spot you) because we're answering all these questions and more on this week's episode of Schauer Thoughts! Stop putting off those doctors appointments and go to https://Zocdoc.com/SCHAUER to find and instantly book a top-rated doctor today.  For a limited time, get Headspace FREE for 60 days. Go to https://Headspace.com/SCHAUER Articles: Anti-intellectualism  https://www.ebsco.com/research-starters/social-sciences-and-humanities/anti-intellectualism Exploring the Reasons Behind Parental Refusal of Vaccines https://pmc.ncbi.nlm.nih.gov/articles/PMC4869767/ Information Density https://publish.obsidian.md/pkc/Hub/Theory/Sciences/information+density The Development of Concrete and Abstract Thinking Patterns  Blog post but clinically reviewed by Tiffany Lovins, Licensed Mental Health Counselor (LMHC) https://calmerry.com/blog/psychology/the-development-of-concrete-and-abstract-thinking-patterns/#:~:text=Abstract%20thinking%20and%20concrete%20thinking%20are%20two,us%20to%20make%20connections%20and%20see%20patterns Cliche's - What is a cliche? https://writingcenter.unc.edu/tips-and-tools/cliches/#:~:text=What%20is%20a%20cliché?,memorable%20contributions%20to%20your%20writing Books: The Knowledge Illusion - Steven Sloman & Philip Fernbach Quoted pages: 175 - 178 Attention: Beyond Mindfulness - Gay Watson If there are any resources I mentioned that are not listed, please let me know and I'll update ASAP. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This is The Digital Story Podcast #995, April 15, 2025. Today's theme is, "Abstract Architecture." I'm Derrick Story. Opening Monologue I found myself sitting in the atrium of a Hyatt Regency looking up. I started to wonder how things would look if I were up there, looking down. What I discovered is a beautiful subject for abstract photography. I tell the story of how this all worked out on today's TDS Photography Podcast. I hope you enjoy the show.

Dr. Refky Nicola summarizes a recent review article from RadioGraphics. Find out how to stand out from the crowd and create your own outstanding exhibit.  Creating an Award-winning RSNA Education Exhibit. Albasha and Burkett et al. RadioGraphics 2022; 42:E106-E108. Check out the new RSNA Education Course about submitting an Abstract for RSNA2025. How To Prepare and Submit an Educational Abstract for the RSNA Annual Meeting (2025)    

Del The Funky Homosapien & thegoodnews "Fakebreaker"Sun Ra "The Cosmic Explorer"The Grateful Dead "Cosmic Charlie (Live)"The 13th Floor Elevators "She Lives (In A Time Of Her Own) (Live)"John Braheny "Silver Cord"Charles Mingus "Duke Ellington's Sound of Love (Live)"Pharoah Sanders "Balance"The Fall "Last Commands of Xyralothep Via M.E.S."

Default deny is an old, and very recognizable term in security. Most folks that have been in the industry for a long time will associate the concept with firewall rules. The old network firewalls, positioned between the public Internet and private data centers, however, were relatively uncomplicated and static. Most businesses had a few hundred firewall rules at most. The idea of implementing default deny principles elsewhere were attempted, but without much success. Internal networks (NAC), and endpoints (application control 1.0) were too dynamic for the default deny approach to be feasible. Vendors built solutions, and enterprises tried to implement them, but most gave up. Default deny is still an ideal approach to protecting assets and data against attacks - what it needed was a better approach. An approach that could be implemented at scale, with less overhead. This is what we'll be talking to Threatlocker's CEO and co-founder, Danny Jenkins, about on this episode. They seemed to have cracked the code here and are eager to share how they did it. This segment is sponsored by ThreatLocker. Visit https://www.securityweekly.com/threatlocker to learn more about them! We wanted security data? We got it! Now, what the heck do we DO with all of it? The core challenge of security operations, incident response, and even compliance is still a data management and analysis problem. Which is why we're seeing companies like Abstract Security pop up to address some of these challenges. Abstract just released a comprehensive eBook on security data strategy, linked below, and you don't even need to give up an email address to read it! In this interview, we'll talk through some of the highlights: Challenges Myths Pillars of a data security strategy Understanding the tools available Segment Resources A Leader's Guide to Security Data Strategy eBook In the enterprise security news, new startup funding what happened to the cybersecurity skills shortage? tools for playing with local GenAI models CVE assignment drama a SIEM-agnostic approach to detection engineering pitch for charity a lost dog that doesn't want to be found All that and more, on this episode of Enterprise Security Weekly. Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-402

Default deny is an old, and very recognizable term in security. Most folks that have been in the industry for a long time will associate the concept with firewall rules. The old network firewalls, positioned between the public Internet and private data centers, however, were relatively uncomplicated and static. Most businesses had a few hundred firewall rules at most. The idea of implementing default deny principles elsewhere were attempted, but without much success. Internal networks (NAC), and endpoints (application control 1.0) were too dynamic for the default deny approach to be feasible. Vendors built solutions, and enterprises tried to implement them, but most gave up. Default deny is still an ideal approach to protecting assets and data against attacks - what it needed was a better approach. An approach that could be implemented at scale, with less overhead. This is what we'll be talking to Threatlocker's CEO and co-founder, Danny Jenkins, about on this episode. They seemed to have cracked the code here and are eager to share how they did it. This segment is sponsored by ThreatLocker. Visit https://www.securityweekly.com/threatlocker to learn more about them! We wanted security data? We got it! Now, what the heck do we DO with all of it? The core challenge of security operations, incident response, and even compliance is still a data management and analysis problem. Which is why we're seeing companies like Abstract Security pop up to address some of these challenges. Abstract just released a comprehensive eBook on security data strategy, linked below, and you don't even need to give up an email address to read it! In this interview, we'll talk through some of the highlights: Challenges Myths Pillars of a data security strategy Understanding the tools available Segment Resources A Leader's Guide to Security Data Strategy eBook In the enterprise security news, new startup funding what happened to the cybersecurity skills shortage? tools for playing with local GenAI models CVE assignment drama a SIEM-agnostic approach to detection engineering pitch for charity a lost dog that doesn't want to be found All that and more, on this episode of Enterprise Security Weekly. Visit https://www.securityweekly.com/esw for all the latest episodes! Show Notes: https://securityweekly.com/esw-402

We wanted security data? We got it! Now, what the heck do we DO with all of it? The core challenge of security operations, incident response, and even compliance is still a data management and analysis problem. Which is why we're seeing companies like Abstract Security pop up to address some of these challenges. Abstract just released a comprehensive eBook on security data strategy, linked below, and you don't even need to give up an email address to read it! In this interview, we'll talk through some of the highlights: Challenges Myths Pillars of a data security strategy Understanding the tools available Segment Resources A Leader's Guide to Security Data Strategy eBook Show Notes: https://securityweekly.com/esw-402

Tune in live every weekday Monday through Friday from 9:00 AM Eastern to 10:15 AM.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Buy our NFT⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Join our Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out our Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Check out our YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠DISCLAIMER: You should never treat any opinion expressed by the hosts of this content as a recommendation to make a particular investment, or to follow a particular strategy. The thoughts and commentary on this show are an expression of the hosts' opinions and are for entertainment & informational purposes only.

You asked, so I'm answering girl—how the hell do we fuel properly for sprinting? There's a lot of noise out there. Some say “sprints are short, so you don't need much.” But if you've ever sprinted properly—I mean real, all-out, full-body-on-fire kind of sprinting—you'll know that's not true. In this EP, I break down the exact science behind the three energy systems your body uses when sprinting (yes, three—not just one), and then I walk you through how I actually fuel for sprint sessions. I'm talking about real strategy—not theory—what I eat, when I eat it, and why. I'll show you how fuelling well can make the difference between power and burnout. Between flying and flailing. If you're training for performance (or aesthetics), this is a game-changer. Key Takeaways: What energy systems power sprinting (ATP-PCr, glycolytic, and aerobic) Why creatine and carbohydrates are essential for short, explosive efforts What to eat before, during, and after a sprint session for peak performance The difference between fuelling for general training vs sprint-specific sessions How under-fuelling kills your power output and stalls your progress A step-by-step breakdown of my own pre-, intra-, and post-sprint fuelling strategy Why most women aren't actually sprinting hard enough to need advanced fuelling—but how to work up to it How to personalise your sprint fuelling plan based on your intensity, duration, and recovery needs Quotes: “Trying to sprint without fuel is like pushing the gas pedal with an empty tank—it splutters and stalls. That's your body under-fueled.” “It's not just about pre-workout meals. How you fuel across the day—and week—builds your power, not just your plate.” “You don't earn power with discipline. You earn it with precision—and food is part of that precision.” “Most women aren't sprinting hard enough to need intra-workout fuel. But if you are? A couple of dates and some EAAs might just change the game.” “Science is great—but experience is better. I've spent the last year testing this on my own body. Here's what works.” Studies, Research & Protocols Mentioned Smith-Ryan, A.E., Fukuda, D.H., Stout, J.R., et al. (2021). "Creatine Supplementation in Women's Health: A Lifespan Perspective." Published in Nutrients, 13(3): 877.

During the pandemic, Debbie Taylor-Kerman made a big decision. She decided to quit her settled career in the commercial art licensing industry to become a full-time artist. Her most recent work is the subject of a new exhibition at Heath Gallery, "More Love Now", on view through May 3. Taylor-Kerman discusses her story, including her childhood in Scotland to arriving to New York in 1991. She will be hosting an Artist Talk at Heath Gallery on April 12 from 2-4pm.